Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data
BackgroundMedroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA is associated with adverse...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1491032/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557809274028032 |
|---|---|
| author | Luyang Su Ren Xu Yanan Ren Shixia Zhao Weilan Liu Zeqing Du |
| author_facet | Luyang Su Ren Xu Yanan Ren Shixia Zhao Weilan Liu Zeqing Du |
| author_sort | Luyang Su |
| collection | DOAJ |
| description | BackgroundMedroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA is associated with adverse drug reactions. This study aimed to evaluate the adverse events (AEs) associated with MPA in by analyzing real-world data from the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS). By providing a comprehensive assessment of the safety profile of MPA, this study seeks to support informed clinical decision-making.MethodsData covering the period from the first quarter of 2004 to the first quarter of 2024 were collected from the FAERS database. Disproportionality analyses were conducted using several statistical methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayesian geometric mean (EBGM). Additionally, time-to-onset (TTO) analysis was employed to quantify the signals of the MPA-associated AEs.ResultsA comprehensive dataset comprising 21,035,995 AE reports was compiled. Among these, 3,939 women reported using MPA as a contraceptive method. The reports covered 27 system organ classes (SOCs) and 25 high-frequency AE signals. Notably, significant AEs were identified, some of which were not previously detailed in the medication’s prescribing information. Unforeseen significant AEs such as unintended pregnancy (n = 623; ROR, 6.65; ROR025, 6.1; χ2, 2,482.38; PRR, 6.41; EBGM, 5.69; EBGM05, 5.29), bone pain (n = 35; ROR, 13.78; ROR025, 9.4; χ2, 311.2; PRR, 13.75; EBGM, 10.59; EBGM05, 7.69), gait disturbance (n = 34; ROR, 2.82; ROR025, 1.99; χ2, 37.31; PRR, 2.88; EBGM, 2.7; EBGM05, 2.02), dental caries (n = 15; ROR, 23.16; ROR025, 12.32; χ2, 204.26; PRR, 23.14; EBGM, 15.23; EBGM05, 8.98), decrease in blood pressure (n = 15; ROR, 3.88; ROR025, 2.29; χ2, 29.35; PRR, 3.88; EBGM, 3.63; EBGM05, 2.33), and osteonecrosis (n = 9; ROR, 23.44; ROR025, 10.36; χ2, 123.67; PRR, 23.43; EBGM, 15.35; EBGM05, 7.75) were identified as AEs that were not previously outlined in the prescribing information of the medication.ConclusionOur findings align with clinical observations, highlighting the emergence of previously unreported AE signals associated with MPA and their demographic and TTO characteristics. Further pharmaco-epidemiological studies are required to substantiate these observations. |
| format | Article |
| id | doaj-art-938a54d90d614f03947356c92108a7c5 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-938a54d90d614f03947356c92108a7c52025-01-06T10:08:09ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-12-011510.3389/fphar.2024.14910321491032Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system dataLuyang Su0Ren Xu1Yanan Ren2Shixia Zhao3Weilan Liu4Zeqing Du5Physical Examination Center, Hebei General Hospital, Shijiazhuang, ChinaDepartment of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, ChinaDepartment of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, ChinaPhysical Examination Center, Hebei General Hospital, Shijiazhuang, ChinaPhysical Examination Center, Hebei General Hospital, Shijiazhuang, ChinaDepartment of Obstetrics and Gynecology, Second Hospital of Hebei Medical University, Shijiazhuang, ChinaBackgroundMedroxyprogesterone acetate (MPA), a synthetic progestogen, is extensively used for the treatment of various conditions, including contraception, irregular menstruation, functional uterine bleeding, and endometriosis. However, like all pharmaceutical agents, MPA is associated with adverse drug reactions. This study aimed to evaluate the adverse events (AEs) associated with MPA in by analyzing real-world data from the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS). By providing a comprehensive assessment of the safety profile of MPA, this study seeks to support informed clinical decision-making.MethodsData covering the period from the first quarter of 2004 to the first quarter of 2024 were collected from the FAERS database. Disproportionality analyses were conducted using several statistical methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayesian geometric mean (EBGM). Additionally, time-to-onset (TTO) analysis was employed to quantify the signals of the MPA-associated AEs.ResultsA comprehensive dataset comprising 21,035,995 AE reports was compiled. Among these, 3,939 women reported using MPA as a contraceptive method. The reports covered 27 system organ classes (SOCs) and 25 high-frequency AE signals. Notably, significant AEs were identified, some of which were not previously detailed in the medication’s prescribing information. Unforeseen significant AEs such as unintended pregnancy (n = 623; ROR, 6.65; ROR025, 6.1; χ2, 2,482.38; PRR, 6.41; EBGM, 5.69; EBGM05, 5.29), bone pain (n = 35; ROR, 13.78; ROR025, 9.4; χ2, 311.2; PRR, 13.75; EBGM, 10.59; EBGM05, 7.69), gait disturbance (n = 34; ROR, 2.82; ROR025, 1.99; χ2, 37.31; PRR, 2.88; EBGM, 2.7; EBGM05, 2.02), dental caries (n = 15; ROR, 23.16; ROR025, 12.32; χ2, 204.26; PRR, 23.14; EBGM, 15.23; EBGM05, 8.98), decrease in blood pressure (n = 15; ROR, 3.88; ROR025, 2.29; χ2, 29.35; PRR, 3.88; EBGM, 3.63; EBGM05, 2.33), and osteonecrosis (n = 9; ROR, 23.44; ROR025, 10.36; χ2, 123.67; PRR, 23.43; EBGM, 15.35; EBGM05, 7.75) were identified as AEs that were not previously outlined in the prescribing information of the medication.ConclusionOur findings align with clinical observations, highlighting the emergence of previously unreported AE signals associated with MPA and their demographic and TTO characteristics. Further pharmaco-epidemiological studies are required to substantiate these observations.https://www.frontiersin.org/articles/10.3389/fphar.2024.1491032/fullmedroxyprogesterone acetatereal-world data analysisadverse drug eventsFAERSunintended pregnancy |
| spellingShingle | Luyang Su Ren Xu Yanan Ren Shixia Zhao Weilan Liu Zeqing Du Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data Frontiers in Pharmacology medroxyprogesterone acetate real-world data analysis adverse drug events FAERS unintended pregnancy |
| title | Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data |
| title_full | Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data |
| title_fullStr | Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data |
| title_full_unstemmed | Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data |
| title_short | Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data |
| title_sort | safety evaluation of medroxyprogesterone acetate a pharmacovigilance analysis using fda adverse event reporting system data |
| topic | medroxyprogesterone acetate real-world data analysis adverse drug events FAERS unintended pregnancy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1491032/full |
| work_keys_str_mv | AT luyangsu safetyevaluationofmedroxyprogesteroneacetateapharmacovigilanceanalysisusingfdaadverseeventreportingsystemdata AT renxu safetyevaluationofmedroxyprogesteroneacetateapharmacovigilanceanalysisusingfdaadverseeventreportingsystemdata AT yananren safetyevaluationofmedroxyprogesteroneacetateapharmacovigilanceanalysisusingfdaadverseeventreportingsystemdata AT shixiazhao safetyevaluationofmedroxyprogesteroneacetateapharmacovigilanceanalysisusingfdaadverseeventreportingsystemdata AT weilanliu safetyevaluationofmedroxyprogesteroneacetateapharmacovigilanceanalysisusingfdaadverseeventreportingsystemdata AT zeqingdu safetyevaluationofmedroxyprogesteroneacetateapharmacovigilanceanalysisusingfdaadverseeventreportingsystemdata |